Common Contracts
275 similar Sales Agreement contracts by Cabaletta Bio, Inc., 23andMe Holding Co., 2seventy Bio, Inc., others
ANNEXON, INC. COMMON STOCK SALES AGREEMENTSales Agreement • March 26th, 2024 • Annexon, Inc. • Pharmaceutical preparations • New York
CABALETTA BIO, INC. COMMON STOCK SALES AGREEMENTSales Agreement • March 21st, 2024 • Cabaletta Bio, Inc. • Biological products, (no disgnostic substances) • New York
VYNE THERAPEUTICS INC. $50,000,000 SALES AGREEMENTSales Agreement • March 1st, 2024 • VYNE Therapeutics Inc. • Pharmaceutical preparations • New York
ULTRAGENYX PHARMACEUTICAL INC. SALES AGREEMENTSales Agreement • February 21st, 2024 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • New York
Ultragenyx Pharmaceutical Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
ARCUTIS BIOTHERAPEUTICS, INC. $100,000,000 SHARES OF COMMON STOCK PAR VALUE $0.0001 PER SHARE AMENDED AND RESTATED SALES AGREEMENTSales Agreement • January 31st, 2024 • Arcutis Biotherapeutics, Inc. • Pharmaceutical preparations • New York
Reference is made to that certain Sales Agreement, entered into as of May 6, 2021 (the “Original Sales Agreement”), by and between Arcutis Biotherapeutics, Inc., a Delaware corporation (the “Company”), and Cowen and Company, LLC (“Cowen”), as sales agent. The Company and Cowen now intend to enter into this Amended and Restated Sales Agreement (this “Agreement”) to amend and restate the terms of the Original Sales Agreement in its entirety. Therefore, the Company confirms its agreement with Cowen as follows:
NEWAMSTERDAM PHARMA COMPANY N.V. ORDINARY SHARES SALES AGREEMENTSales Agreement • December 7th, 2023 • NewAmsterdam Pharma Co N.V. • Pharmaceutical preparations • New York
NewAmsterdam Pharma Company N.V., a public limited liability company (naamloze vennootschap) incorporated under the laws of the Netherlands (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
SAGE THERAPEUTICS, INC. SHARES OF COMMON STOCK, PAR VALUE $0.0001 PER SHARE SALES AGREEMENTSales Agreement • November 7th, 2023 • Sage Therapeutics, Inc. • Pharmaceutical preparations • New York
VIR BIOTECHNOLOGY, INC. COMMON STOCK SALES AGREEMENTSales Agreement • November 3rd, 2023 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
Vir Biotechnology, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
ATARA BIOTHERAPEUTICS, INC. COMMON STOCK SALES AGREEMENTSales Agreement • November 1st, 2023 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
Entrada Therapeutics, Inc. SHARES OF Common Stock, PAR VALUE $0.0001 SALES AGREEMENTSales Agreement • September 29th, 2023 • Entrada Therapeutics, Inc. • Pharmaceutical preparations • New York
Entrada Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
CUE HEALTH INC. COMMON STOCK SALES AGREEMENTSales Agreement • August 9th, 2023 • Cue Health Inc. • Laboratory analytical instruments • New York
Cue Health Inc., a Delaware corporation, (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
SERES THERAPEUTICS, INC. COMMON STOCK SALES AGREEMENTSales Agreement • August 8th, 2023 • Seres Therapeutics, Inc. • Pharmaceutical preparations • New York
SOPHiA GENETICS SA SALES AGREEMENTSales Agreement • August 8th, 2023 • SOPHiA GENETICS SA • Biological products, (no disgnostic substances) • New York
SOPHiA GENETICS SA, a corporation (société anonyme) incorporated under the laws of Switzerland (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
SYNDAX PHARMACEUTICALS, INC. common Stock (par value $0.0001 per share) SALES AGREEMENTSales Agreement • May 26th, 2023 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
Syndax Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
Terns Pharmaceuticals, Inc. SHARES of Common Stock, Par Value $0.0001 SALES AGREEMENTSales Agreement • May 15th, 2023 • Terns Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Terns Pharmaceuticals, Inc., a Delaware company (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
ADVERUM BIOTECHNOLOGIES, INC. COMMON STOCK SALES AGREEMENTSales Agreement • May 11th, 2023 • Adverum Biotechnologies, Inc. • Biological products, (no disgnostic substances) • New York
Adverum Biotechnologies, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
ITEOS THERAPEUTICS, INC. UP TO $125,000,000 OF SHARES OF COMMON STOCK SALES AGREEMENTSales Agreement • May 10th, 2023 • iTeos Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
iTeos Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
KRYSTAL BIOTECH, INC. Common Stock (par value $0.00001 per share) SALES AGREEMENTSales Agreement • May 8th, 2023 • Krystal Biotech, Inc. • Biological products, (no disgnostic substances) • New York
Krystal Biotech, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
ALPINE IMMUNE SCIENCES, INC. $100,000,000 OF SHARES OF COMMON STOCK SALES AGREEMENTSales Agreement • April 28th, 2023 • Alpine Immune Sciences, Inc. • Pharmaceutical preparations • New York
Alpine Immune Sciences, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
AVITA MEDICAL, INC. SHARES OF COMMON STOCK SALES AGREEMENTSales Agreement • April 14th, 2023 • AVITA Medical, Inc. • Surgical & medical instruments & apparatus • New York
AVITA Medical, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
SALES AGREEMENTSales Agreement • April 14th, 2023 • New York
AVITA Medical, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
SYROS PHARMACEUTICALS, INC. COMMON STOCK SALES AGREEMENTSales Agreement • April 6th, 2023 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Syros Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
AN2 THERAPEUTICS, INC. COMMON STOCK SALES AGREEMENTSales Agreement • April 6th, 2023 • AN2 Therapeutics, Inc. • Pharmaceutical preparations • New York
Alpha Teknova, Inc. COMMON STOCK SALES AGREEMENTSales Agreement • March 30th, 2023 • Alpha Teknova, Inc. • In vitro & in vivo diagnostic substances • New York
Intercept Pharmaceuticals, Inc. SALES AGREEMENTSales Agreement • March 24th, 2023 • Intercept Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Intercept Pharmaceuticals, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
CABALETTA BIO, INC. COMMON STOCK SALES AGREEMENTSales Agreement • March 16th, 2023 • Cabaletta Bio, Inc. • Biological products, (no disgnostic substances) • New York
HOMOLOGY MEDICINES, INC. COMMON STOCK SALES AGREEMENTSales Agreement • March 9th, 2023 • Homology Medicines, Inc. • Pharmaceutical preparations • New York
BRIGHTCOVE INC. COMMON STOCK SALES AGREEMENTSales Agreement • February 23rd, 2023 • Brightcove Inc • Services-computer processing & data preparation • New York
Brightcove Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
IO BIOTECH, INC. COMMON STOCK SALES AGREEMENTSales Agreement • February 15th, 2023 • IO Biotech, Inc. • Pharmaceutical preparations • New York
23ANDME HOLDING CO. COMMON STOCK SALES AGREEMENTSales Agreement • February 6th, 2023 • 23andMe Holding Co. • Pharmaceutical preparations • New York
2SEVENTY BIO, INC. COMMON STOCK SALES AGREEMENTSales Agreement • November 18th, 2022 • 2seventy Bio, Inc. • Pharmaceutical preparations • New York
Voyager Therapeutics, Inc. Common STOCk SALES AGREEMENTSales Agreement • November 8th, 2022 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Voyager Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
COHERUS BIOSCIENCES, INC. COMMON STOCK SALES AGREEMENTSales Agreement • November 8th, 2022 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances) • New York
Coherus BioSciences, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
COMMON STOCK SALES AGREEMENTSales Agreement • November 8th, 2022 • AVROBIO, Inc. • Biological products, (no disgnostic substances) • New York
MERSANA THERAPEUTICS, INC. common stock SALES AGREEMENTSales Agreement • November 7th, 2022 • Mersana Therapeutics, Inc. • Pharmaceutical preparations • New York
Mersana Therapeutics, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
